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AmyloidFollicular lymphoma (FL) and marginal zone lymphoma (MZL) are distinct clinicopathologic entities de-
rived from small B-cells. Here we report an unusual case of simultaneous occurrence of CD10-negative,
t(14;18)/BCL2-negative FL with rare residual germinal centers, and extranodal MZL with extensive amyloid
deposition. Diagnostic challenges included a prominent nodular growth pattern and lack of expression of
commonly used germinal center (GC) B-cell markers and the t(14;18)/BCL2 gene rearrangement character-
istic of FL in an inguinal lymph node. The corresponding chest wall mass was diagnosed as MZL with exten-
sive amyloid deposition. Though initially diagnosed as MZL involving a lymph node corresponding to the
chest wall mass, newer markers of GC B-cells, HGAL and LMO2, as well as a newly described marker of mar-
ginal zone cells, MNDA, were helpful to establish the diagnosis of FL in the inguinal lymph node. Subsequent
molecular clonality studies showed two distinct clonal B-cell processes in the two sites. This case illustrates
the need for integration of morphologic ﬁndings with careful choice of ancillary diagnostic tests to establish
deﬁnitive diagnoses among the spectrum of lymphomas derived from small B-cells.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Lymphomas derived from small B-cells exhibit a spectrum of clinical
behavior and include indolent lymphomas that may not require treat-
ment to those that have a propensity to transform to an aggressive lym-
phoma or remain refractory to therapy [1]. These lymphomas include
follicular lymphoma (FL), marginal zone lymphoma (MZL),
lymphoplasmacytic lymphoma (LPL), chronic lymphocytic leukemia
(CLL)/small lymphocytic lymphoma (SLL), mantle cell lymphoma
(MCL), and hairy cell leukemia (HCL) [1]. Clinically, patients may be
asymptomatic or present with lymphadenopathy, splenomegaly,235, Stanford University School
4, United States. Tel.: +1 650
. This is an open access article undersystemic symptoms or cytopenia arising from bone marrow involve-
ment. Although accurate diagnosis of this spectrum of lymphomas is
important for appropriate clinical management, speciﬁcmarkers for de-
ﬁnitive subclassiﬁcation are not always available.
The separation of FL from nodal MZL can be particularly challenging
in a subset of cases where there is a nodular growth pattern: FL inﬁl-
trates may extend into the interfollicular space and show diffuse in-
volvement or marginal zone differentiation [2,3], mimicking MZL,
whereas MZL may show follicular colonization [4,5]. A subset of FL
may also lack expression of commonly used GC B-cell markers such as
CD10 and BCL6. AlthoughHGAL and LMO2 are newer sensitive and spe-
ciﬁc markers for FL [6–8], they are not always employed in routine
immunohistologic panels. Fluorescence in situ hybridization (FISH) for
the t(14;18)/BCL2 gene rearrangement is very helpful in the diagnosis
of FL, although a subset of FL lack this translocation. MZL has a less dis-
tinct immunophenotype, but co-expression of CD43 on B-cells, expres-
sion of MNDA [9,10], or the AP12-MALT1 translocation, when present,
may aid in the diagnosis of MZL.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Reagents and conditions used for immunohistochemistry
Antibody Clone Dilution Platform/Conditions Manufacturer
CD20 L26 1:1000 Ventana XT; Standard retrieval Dako, Capinteria, CA
CD79a JCB117 1:40 Ventana XT; Standard retrieval Dako, Capinteria, CA
CD3 Rabbit polyclonal 1:50 Ventana XT; Standard retrieval Cell Marque, Rocklin, CA
CD5 4C7 1:100 Ventana XT; Standard retrieval Leica, Newcastle-upon-Tyne, UK
BCL2 E17 1:50 Leica Bond-Max; ER2 retrieval Epitomics
CD10 56C6 1:80 Leica Bond-Max; ER2 retrieval Leica, Newcastle-upon-Tyne, UK
BCL6 GL191E/A8 1:100 Ventana XT; Standard retrieval Cell Marque, Rocklin, CA
HGAL MRQ 1:100 Leica Bond-Max; ER2 retrieval Cell Marque, Rocklin, CA
LMO2 1A9-1 1:4 Leica Bond-Max; ER2 retrieval Ventana, Tucson, AZ
MNDA 235A/G1 1:50 Leica Bond-Max; ER2 retrieval Courtesy of G. Roncador, CNIO, Spain
BCL1 SP4 1:50 Ventana XT; Standard retrieval Thermo-Fisher Scientiﬁc
IgA NICLA 1:200 Ventana XT; Standard retrieval Leica, Newcastle-upon-Tyne, UK
IgG RWP49 1:400 Leica Bond-Max; ER2 retrieval Leica, Newcastle-upon-Tyne, UK
IgM Polyclonal 1:1250 Ventana XT; Standard retrieval Dako, Capinteria, CA
Kappa Rabbit polyclonal 1:1000 Ventana XT; Protease 2 retrieval Dako, Capinteria, CA
Lambda Rabbit polyclonal 1:4000 Ventana XT; Protease 2 retrieval Dako, Capinteria, CA
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and extranodal MZL involving soft tissue of the chest wall, in a patient
with a history of extranodal MZL and CLL/SLL. This case raised the fol-
lowing important considerations: (1) awareness of FL and MZL as a dif-
ferential diagnostic consideration in atypical lymphoid proliferations
showing a nodular/follicular growth pattern; (2) the need for a high
index of suspicion in the workup of small B-cell lymphomas with atyp-
ical immunophenotypic and cytogenetic features; and (3) consideration
of two synchronous processes rather than one process with multisite
involvement.2. Case report
An 82-year-old man presented with unexplained weight loss
over a period of 6 months. His past medical history included CLL/
SLL in 1997, which was diagnosed on a bonemarrow biopsy and con-
ﬁrmed by peripheral blood ﬂow cytometry. In 1999, he was found to
have extranodal MZL causing small bowel obstruction, which neces-
sitated segmental resection. He received six cycles of RCHOP (Ritux-
imab, cyclophosphamide, doxorubicin, vincristine, prednisone) for
advanced stage disease and achieved complete clinical and radio-
graphic remission. The patient also had a history of prostate carcino-
ma, status post transurethral resection of the prostate, and
melanoma and basal cell carcinoma diagnosed on skin biopsies. The
prior lymphoma specimens from the outside facility were not avail-
able for review or further study.
In 2013, the patient presented with unexplained weight loss
without abdominal pain, fevers, night sweats or chills. On physical
examination, inguinal lymphadenopathy was detected. A positron
emission tomography-computed tomography (PET-CT) scan showed
multiple sites of disease: right inguinal lymphadenopathy, masses in
the upper abdomen and pelvic sidewall, and a hypermetabolic mass
extending from beneath the left clavicle to the base of the left neck.
There was no hepatosplenomegaly. An excisional biopsy of a right in-
guinal lymph node and an incisional biopsy of the left chest wall
mass were carried out. Initial morphologic and immunophenotypic
analysis led to the diagnosis of extranodal MZL involving both the
chest wall and inguinal lymph node. The chest wall mass was associ-
ated with extensive amyloid deposition but amyloid was not detect-
ed in the lymph node. FISH analysis for t(14;18)/BCL2 gene
rearrangement was performed on the inguinal lymph node and
was negative (which was repeated and included an appropriate pos-
itive control), which led to additional immunohistochemistry and
molecular clonality studies for further workup. These studiesconﬁrmed involvement by two separate lymphomas harboring two
different B-cell clonal processes, and led to a revised diagnosis of FL
in the inguinal lymph node. The patient was treated with 6 cycles
of bendamustine and rituximab, which was completed in June
2014. He remains free of clinical evidence of disease at one-year
post treatment.3. Materials and methods
The case was sent in consultation to the Department of Pathology at
Stanford University Medical Center. All investigations were carried out
with the approval of the Institutional Review Board of Stanford
University.
Immunohistochemistry was performed using automated platforms,
Ventana XT autostainer, Ventana Medical Systems Inc., Tucson, AZ or
Leica Bond-Max autostainer, Leica Microsystems Inc., Buffalo Grove, IL,
and included the following markers: CD20, CD79a, CD3, CD5, BCL2,
CD10, BCL6, HGAL, LMO2, MNDA, BCL1, IgA, IgG, IgM, and kappa
and lambda light chains (Table 1). Polymerase chain reaction (PCR)
for B cell clonality was performed as previously described [11].
Flow cytometry was performed at an outside institution and was
reviewed.
For FISH, a BCL2 dual-color breakapart probe (ZytoVision, Bre-
merhaven, Germany) was used according to methodology that
was previously described [12]. PCR was performed using
BIOMED-2 primers to detect rearrangements of IGH and IGK,
followed by differential ﬂuorescence detection using GeneScan
analysis (Life Technologies, Foster City, CA), as previously de-
scribed [11]. For detection of MYD88 L265P mutation, a single
base extension assay using a MYD88 probe with interrogation of
the L265 locus was used [13].4. Results
Fig. 1 shows representative images of the right inguinal lymph
node with effacement of the nodal architecture by back-to-back,
variably sized follicles with focal, small, residual germinal centers
and attenuated mantle zones. The neoplastic cells, which ﬁlled the
majority of the nodules, were composed of a monotonous popula-
tion of small cells with irregular, angulated nuclei. The atypical pro-
liferationwas positive for CD20 and BCL2 but lacked CD3, CD5, CD10,
BCL1 and SOX11. There was focal BCL6 staining in what appeared to
be residual germinal centers, which were also highlighted by Ki-67.
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Table 2
Summary of ancillary studies in the inguinal lymph node and chest wall mass
Test Inguinal LN Chest wall
CD20, CD79a, CD19 Positive Positive
CD3, CD5 Negative Negative
CD10 Negative Negative




BCL1, SOX11 Negative Not performed
MNDA Negative Weak positive
Ig heavy chain (IgM/IgG/IgA) IgM Not informative (high background)
Ig kappa/lambda light chains (ﬂow/IHC/ISH) Kappa Not informative (high background)
Congo red Negative Positive
FISH t(14;18)/BCL2 Negative Not performed
MYD88 L265Pmutation Not performed Negative
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ic cell meshworks. Immunoglobulin heavy chain stains show ex-
pression of IgM by the neoplastic cells. Flow cytometry conﬁrmed
a CD10 and CD5-negative, kappa light chain-restricted B-cell popu-
lation. FISH for t(14;18)/BCL2 gene rearrangement was negative
(Table 2).
Fig. 2 shows representative images of the chest wall mass with ex-
tensive lamellar appearing structures of acellular material associated
with focal metaplastic bone and cartilage. Rare multinucleated giant
cells were intermingled with aggregates of small round lymphoid cells
with moderate amounts of cytoplasm. Although these B-cells showed
monocytoid differentiation, admixed plasma cells were rare. A Congo
red stain highlighted the acellular material and showed an apple
green birefringence under polarized light, which was consistent with
amyloid. Immunohistochemical stains for CD20, CD79a, CD3, and CD5
showed that the lymphoid cells were composed almost entirely of B-
cells with a few scattered T-cells. Similar to the inguinal lymph node,
BCL2 stained themajority of cells while CD10, BCL6 and BCL1were neg-
ative, which made the considerations of FL and MCL unlikely. The
MYD88 L265Pmutation was not detected by PCR, providing no support
for a lymphoplasmacytic lymphoma. Taken together, the ﬁndings in the
inguinal lymph node and chest wall mass led to the diagnosis of
extranodalmarginal zone lymphomaassociatedwith extensive amyloid
deposition in the chest wall.
Residual germinal centers in the center of the enlarged nodules of
an atypical lymphoid inﬁltrate in the inguinal lymph node were un-
usual, and a further workup with newer germinal center markers
HGAL and LMO2 was undertaken. These markers were both strongly
positive in the lymph node, which is typical of follicular lymphoma,
but were negative in the chest wall mass (Fig. 1K–L and Fig. 2H–I in-
sets). In addition, an MNDA stain showed weak staining in the chest
wall mass (Fig. 2I), which is characteristic of MZL, but was negative
in the lymph node.Fig. 1Morphologic and immunophenotypic ﬁndings in the inguinal lymph node. Representative
back-to-back follicles, with focal, small, residual germinal centers (A–C). The neoplastic cells are
(G) and show focal expression of BCL6 (H). Ki67 stains residual germinal center B-cells (I). CD2
(K) and LMO2 (L) show strong positive staining in the majority of the neoplastic cells. Ig heavy
gene rearrangement was negative (P). Original magniﬁcations: ×100–×600.To compare whether the lymph node and chest wall mass
showed similar or disparate clonal B-cell processes, molecular
clonality studies were performed. The right inguinal lymph node
specimen was positive for IGH with strong clonal peaks in FR1, FR2
and FR3, and was negative for IGK. The left chest wall mass specimen
demonstrated a weak but reproducible peak in the FR2 region of the
IGH assay at a different location to the clonal peak detected in the
concurrent right inguinal lymph node specimen. The left chest wall
mass was negative for IGK. Together, these ﬁndings were consistent
with involvement by two different clonal processes in the two sites
(Fig. 3).5. Discussion
The histologic differential diagnosis of an atypical lymphoid
proliferation in a nodular pattern requires correlation with
immunophenotype and molecular ﬁndings for accurate diagnosis.
The case presented here illustrates the following diagnostic pit-
falls: (1) both FL and MZL involving the lymph node can have a
prominent nodular growth pattern; (2) both can show residual
GC with tingible body macrophages and increased proliferation;
(3) BCL6 positivity can be variable and mimic follicular coloniza-
tion by MZL; (4) both FL and MZL can have BCL2-positive nodules
and lack t(14;18)/BCL2 gene rearrangement; and (5) CD10-
negative FL can mimic MZL.
At the time of consultation, the patient had presented with unex-
plained weight loss and an enlarging chest wall mass, in addition to
multisite disease highlighted by PET-CT. Given his complicated past
medical history of hematolymphoid malignancy, including CLL/SLL
and MZL, as well as prostate carcinoma, melanoma, and basal cell
carcinoma, his clinical presentation elicited a wide range ofsections of the inguinal lymph node show effacement of the normal nodal architecture by
small with angulated nuclei (D), and are positive for CD20 (E) and BCL2 (F), but lack CD10
1 highlights follicular dendritic cell meshworks (J). Germinal center B-cell markers HGAL
chain stains show IgM positivity (M) and lack IgG (N) and IgA (O). FISH for t(14;18)/BCL2
Fig. 2.Morphologic and immunophenotypic ﬁndings in the chest wall mass. Representative sections of the chest wall mass showmassive deposition of acellular material associated with
metaplastic bone and cartilage (A–B), intermingled with aggregates of small lymphoid cells (C). Congo red stain highlights amyloid (D) and shows apple green birefringence under po-
larized light (E). Immunohistochemical stains show positivity for CD79a (F) and BCL2 (G), and lack CD10 and HGAL (H and inset). MNDA shows weak nuclear staining characteristic of
marginal zone lymphoma (I), and inset in panel I shows the lack of LMO2. Original magniﬁcations: ×100–×600.
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Fig. 3. Comparison of fragment size analysis of clonal rearrangement of IGH gene detected by PCR assay in the inguinal lymph node and chest wallmass. The inguinal lymph node specimen shows strong IGH clonal peaks in FR1, FR2 and FR3 indicative
of clonal IGH rearrangement. The peak at 149 in Vk1f_6_Vk7_Jk is a frequently seen nonspeciﬁc amplicon and is not indicative of clonality. The chest wallmass demonstrated aweak but reproducible peak in the FR2 region at a different location to that
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and carcinoma. The duplicate biopsies conﬁrmed lymphoma but ne-
cessitated an extensive workup, which ultimately resulted in two
separate lymphoma diagnoses. Although both lymphomas were in-
dolent and bendamustine and rituximab are an effective combina-
tion for a subset of recurrent indolent lymphomas, they are not
always the ﬁrst or only choice available. Newer agents such as the
BTK-inhibitor ibrutinib, have become available and offer the oppor-
tunity for further optimizing management in the setting of recurrent
indolent lymphomas. The association of amyloidosis with certain
lymphomas derived from small B-cells but not others is another as-
pect of this case that is important to guide further systemic workup
such as for plasma cell myeloma. Accurate subclassiﬁcation is also
important to monitor disease course, progression and overall prog-
nosis. Therefore, subtyping lymphomas derived from small B-cells
helps optimize treatment regimens and ensures that the patient is
appropriately managed. In addition, accurate subclassiﬁcation at all
age groups allows the opportunity to collect well-annotated data
for clinical protocols and future studies.
The neoplastic cells in the chest wall mass expressed CD20 and
MNDA and showed a clonal B-cell receptor gene rearrangement, but
lacked CD5, BCL1, CD10, BCL6, HGAL, LMO2, t(14;18)/BCL2 gene rear-
rangement and theMYD88 L265Pmutation, which supported a diagno-
sis of MZL. The massive amyloid deposition associated with the chest
wall mass has been previously reported in rare cases of MZL
and was found to be localized without systemic manifestations
[14]. In keeping with those observations, amyloid deposition
was localized to the chest wall mass but was not found in the
lymph node.
The right inguinal lymph node proved to be more diagnostically
complex. The most common small B-cell lymphoma exhibiting a
nodular/follicular growth pattern in this setting, FL, was initially
not supported given that the majority of the neoplastic cells lacked
GC B-cell markers CD10 and BCL6, as well as the t(14;18)/BCL2
gene rearrangement. In addition, given the ﬁndings in the chest
wall mass with extensive amyloid deposition, it seemed likely that
the inguinal lymph node also represented MZL with follicular coloni-
zation [2,3], and led to the erroneous diagnosis of MZL in the ingui-
nal lymph node.
Newer markers of GC B-cells, HGAL and LMO2 [6–8], as well as a
newly described marker of marginal zone cells, MNDA [9,10], were
then employed and were helpful to establish the diagnosis of FL in the
inguinal lymph node andMZL in the chest wall mass. These separate di-
agnoses were further conﬁrmed by clonality studies that demonstrated
disparate clonal B-cell processes in the two sites. Several FL variants that
lack t(14;18) have been recently described at the molecular level, and
include those with BCL6 gene ampliﬁcation/3q27 gain, overexpression
of MUM1/IRF4, and pediatric FL with grade 3 morphology with either
strong MUM1/IRF4 expression or rarely IRF4 translocation-negative
cases with deletions at 1p36 involving TNFRSF14 [14–19]. The clinical,
cytologic and immunophenotypic features of the current case do not
ﬁt into any of these recently describedmolecular entities: the exact mo-
lecular defect leading to this t(14;18)-negative FL in an 82-year old pa-
tient remains unclear.
Rare cases of synchronous FL andMZL have been reported previous-
ly. Those cases were associated with chronic inﬂammatory processes
such as Sjögren's syndrome presenting with MZL of the parotid gland
or a history of epigastric pain presenting with gastric MZL in a back-
ground of Helicobacter pylori gastritis [20,21]. Our patient had no
known risk factors associated with MZL, except his prior history of
MZL. In the reported cases of synchronous FL and MZL, the FL compo-
nent presented with typical morphologic, immunophenotypic, and ge-
netic ﬁndings including the t(14;18)/BCL2 gene rearrangement. The
two lymphomas also shared a clonal relationship raising the possibility
that lymphomas with two divergent phenotypes evolved at different
sites from a single pre-malignant t(14;18)-bearing B-cell. In the currentcase, however, molecular clonality studies conﬁrmed the occurrence of
two distinct and unrelated lymphomas presenting simultaneously in
this patient.6. Conclusions
We present an unusual adult patient with simultaneous occur-
rence of two clonally distinct lymphomas derived from small B-
cells, FL andMZL, involving two separate sites. A nodular growth pat-
tern together with the absence of typical immunophenotypic and
molecular markers of FL, initially led to an erroneous diagnosis; how-
ever, using a new generation of germinal center (HGAL and LMO2)
and marginal zone B-cell markers (MNDA) and B cell receptor gene
rearrangement studies, the presence of two distinct lymphomas
was conﬁrmed. This case illustrates the need for integration of mor-
phologic ﬁndings with careful choice of ancillary diagnostic tests to
establish a deﬁnitive diagnosis.References
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